Peptide Based Cancer Therapeutics Market Share, Trends, Business Strategy and Forecast 2017 to 2022

Peptide based cancer therapeutics are yet to become widespread, but the initial low numbers certainly do not suggest any pessimism in the global market. With new developments in delivery, stability, modifications, and preclinical success, future growth potentials of such cancer therapeutics continue to intensify. A slew of new peptides with positive preclinical results are entering into clinical trials that are focused on cancer treatment. Moreover, the application base of peptides is steadily expanding to other therapeutic areas as well. In the near future, the global peptide based cancer therapeutics market is likely to be influenced by the rising prevalence of cancer across the globe. WHO reveals that cancer is one of the leading causes of death worldwide, which accounted for more than 8 million deaths in 2015. Factor as such are expected to play an important role in boosting the popularity of peptide based cancer therapeutics further. In addition, various complications involved in conventional cancer therapeutics as well as the risk of sever side-effects are prompting medical professionals to utilise peptides in tumor and cancer treatment. Fact.MR’s latest report projects that the global peptide based cancer therapeutics market will surpass a valuation of US$ 11,160 Mn by 2022-end, expanding at an impressive CAGR of 9.2% during the forecast period (2017-2022).

According to a report published by Fact.MR, the global peptide based cancer therapeutics market is poised to surpass the market valuation of US$ 11,000 Mn by the end of 2022, owing to multiple factors contributing to this boom.

Get Free Sample Report Here:

Medical institutions across the world are ramping up their efforts towards the development of effective therapeutic drugs for cancer treatment. In addition to this, investors are underpinning the initiatives of healthcare organizations by funding their researches. With the report produced by the World Health Organization (WHO) stating the occurrence of over 8 Mn deaths in 2015 backed by the pervasiveness of cancer, proliferating adoption of advanced peptide based cancer therapeutic is witnessed. A host of these factors have contributed to the growing size of the peptide-based cancer therapeutics market at the global level with an estimated CAGR of over 9% through 2022.

The Fact.MR report provides segment-wise analysis and forecast for covering the wide scope of global peptide based cancer therapeutics market. Drug, distribution channel and region are key segments that define the growth of the global market for peptide based cancer therapeutics. In this segmentation analysis, a detailed country-wise forecast across all key market parameters is also included.

North America To Lead The Global Peptide Based Cancer Therapeutics Market

In terms of revenues, North America is expected to dominate the global peptide based cancer therapeutics market in 2017 and beyond. The region’s potency in healthcare and a strong presence of various peptide based cancer therapeutic drug manufacturers is supporting the growth of the market in North America. During the forecast period, the market in the region is expected to surge at a robust CAGR.

On the basis of drugs, the bortezomib segment is expected to remain highly attractive throughout the assessment period. The segment currently accounts for around 40% revenue share of the global market. Between 2017 and 2022, the segment is expected to reflect a double-digit CAGR to reach a valuation is excess of US$ 4,725 Mn. It expected to grow at US$ 358.4 Mn annually over the course of the forecast period.

An analysis of the supply chain and average pricing is discussed in the report to understand the dynamics of the peptide-based cancer therapeutics market. Evaluation of the attractiveness of the market has been carried out on the basis of region, drug, and distribution channel.

The regions analyzed in the report consist of Latin America, North America, Europe, Japan, Asia Pacific except Japan (APEJ), and the Middle East and Africa (MEA). The regions have been analyzed keeping the segments – drug and distribution channel and their revenue share to the global market in mind.

Valeant Pharmaceuticals International, Inc., Allergan plc, AbbVie Inc., AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Abbott, Pfizer Inc., and Johnson & Johnson are among the leading companies functioning in the global market for peptide based cancer therapeutics. Majority of these market players are actively focusing on further product development as well as channelizing their investments in R&D activities.

Have Any Query?? Ask Our Industry Expert

About Fact.MR

Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.

Contact Us


11140 Rockville Pike

Suite 400

Rockville, MD 20852

United States